News

The majority of adverse effects reported were considered mild.

While obesity is less common in pediatric sickle cell patients, BMI may impact airway resistance in this population.

The smart pen cap system is associated with real-time hypoglycemia alerts and insulin dose recommendations.

A new study presented at ASGCT found that patients with indications of hemostatic efficacy experienced few adverse effects with gene therapy treatment BAY 2599023.

More than 3000 people per day in India have died of COVID-19 since April 28.

Meredith McCormack, MD discusses consequences of high air pollution levels in the United States found in the 2021 American Lung Association State of the Air Report.

Early results from the MOMENTUM study show that treated patients experienced fewer vaso-occlusive episodes and related hospital admissions.

More than 40% of the treatment arm of the placebo-controlled trial achieved a complete renal response.

Histologic scores in the endoscopically involved mucosa of index biopsies not linked to subsequent extension of ulcerative colitis.

Climate change health experts Poune Saberi, MD, and Alan S. Greenglass, MD, join Lungcast for a timely discussion on environmental health issues.

Dr. Todd Hutton gives tips for how to best handle the ongoing mental health crisis.

Research at ARVO 2021 highlighted a gamut of interplaying diabetes and vision loss risk factors, and even treatments for both. But experts depict a referral and care process that lacks whole diabetes care.

New data show NSAIDs treatment not associated with worse in-hospital mortality rates compared to patients not treated with NSAIDs.

A recent JAMA study shows a decrease in suicide deaths between 2019-2020, despite a 17% overall increase in mortality.

A podcast interview with study author Paul Yang, MD, PhD, on the current research and future implementation of the agent.

Data from the KITE study shows that ≥50% of brolucizumab patients maintained a 12-week interval schedule through 52 weeks.

Patients who utilized virtual and in-person visits had comparable numbers of follow-ups, referrals, and outpatient surgeries.

New data show rheumatoid arthritis and immunosuppressive treatment associated with more severe risks of COVID-19, including hospitalization and death.

The companies announce plans to submit a Biologics License Agreement for the mRNA-based vaccine.

James Januzzi, MD, and Javed Butler, MD, MPH, MBA, discuss emerging agents, vericiguat and intravenous (IV) iron, in the treatment landscape for heart failure with reduced ejection fraction and advice for community physicians managing patients with heart failure.

The CDC currently recommends every pregnant woman screened for hepatitis C virus.

The implant was linked to visual acuity improvements at final follow-up visit.

Animal models suggest the investigative treatment is safe and tolerable in treating retinal vascular diseases.

A new study finds the top 10 future research priorities into diabetes and pregnancy.

There were no significant differences between dexamethasone and fluocinolone acetonide intravitreal implants in controlling inflammation; however, the latter is considered more difficult to use.

New data show immunosuppressant treatment did not increase susceptibility to or severity of COVID-19 in patients with immune-mediated inflammatory disease

A discussion with an investigator on how the SGLT-2 inhibitor may help affected patients.

Up to 77% of patients maintained or improved best-corrected visual acuity at 12 month post-injection.

Hispanic and Black patients with chronic eye diseases had higher odds of missing out on appointments.

Investigators report a low incidence rate of unscheduled or urgent visits within 7 days of injection.